227. オスラー病 Osler disease Clinical trials / Disease details


臨床試験数 : 56 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

  
16 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100043253
2021-02-172021-02-09The study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab in the treatment of refractory epistaxis caused by HHTThe study of genotype analysis of HHT patients in china and clinical efficacy study of bevacizumab in the treatment of refractory epistaxis caused by HHT hereditary hemorrhagic telangiectasiaTrial group:Bevacizumab;Shandong Provincial ENT HospitalNULLRecruiting1675BothTrial group:30;Phase 4China
2NCT04404881
(ClinicalTrials.gov)
November 23, 202022/5/2020Bevacizumab In Hereditary Hemorrhagic TelangiectasiaA Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: BevacizumabHanny Al-Samkari, MDNULLRecruiting18 YearsN/AAll20Phase 2United States
3NCT03227263
(ClinicalTrials.gov)
September 28, 201721/7/2017BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III StudyRendu Osler Disease;Telangiectasia, Hereditary HemorrhagicDrug: Bevacizumab;Drug: sodium chloride 0.9%Hospices Civils de LyonNULLCompleted18 YearsN/AAll24Phase 3France
4EUCTR2017-001031-39-FR
(EUCTR)
19/05/201719/06/2020BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT)BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study. - BABH Hemorrhagic Hereditary Telangiectasia
MedDRA version: 20.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: AVASTIN
Product Name: BEVACIZUMAB
INN or Proposed INN: BEVACIZUMAB
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
24Phase 3France
5NCT02157987
(ClinicalTrials.gov)
December 15, 20144/6/2014Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTreatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective DoseTelangiectasia, Hereditary HemorrhagicDrug: bevacuzimab sprayUniversity Hospital, CaenNULLRecruiting18 Years70 YearsAll30Phase 1/Phase 2France
6NCT02389959
(ClinicalTrials.gov)
August 4, 201411/3/2015Intranasal Bevacizumab for HHT-Related EpistaxisIntranasal Bevacizumab for HHT-Related EpistaxisHHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal BleedingDrug: Bevacizumab;Drug: Placebo (Saline)Stanford UniversityNULLCompleted18 YearsN/AAll40Phase 4United States
7NCT02106520
(ClinicalTrials.gov)
April 20141/4/2014Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia;EpistaxisDrug: Bevacizumab;Drug: placeboHospices Civils de LyonNULLTerminated18 YearsN/ABoth80Phase 2/Phase 3France
8EUCTR2013-004204-19-FR
(EUCTR)
26/02/201416/06/2015Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-OslerEfficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORI Rendu-Osler disease
MedDRA version: 18.0;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Avastin
Product Name: Avastin
INN or Proposed INN: BEVACIZUMAB
Hospices Civils de LyonNULLNot RecruitingFemale: yes
Male: yes
France
9NCT01507480
(ClinicalTrials.gov)
October 20116/12/2011The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic TelangiectasiaThe ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.Rendu Osler Disease;Telangiectasia, Hereditary HemorrhagicDrug: BevacizumabHospices Civils de LyonNULLCompleted18 YearsN/AAll42Phase 1France
10NCT01408030
(ClinicalTrials.gov)
August 20111/8/2011North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)North American Study of Epistaxis in HHT (NOSE)Telangiectasia, Hereditary Hemorrhagic;EpistaxisDrug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic AcidJames GossageHHT Foundation InternationalCompleted18 YearsN/AAll123Phase 2United States
11NCT01314274
(ClinicalTrials.gov)
March 20119/3/2011Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic TelangiectasiaHHT;Morbus Osler;EpistaxisDrug: Bevacizumab;Drug: NaClMedical University of ViennaNULLCompleted18 Years80 YearsBoth15Phase 2Austria
12EUCTR2009-018049-19-AT
(EUCTR)
13/12/201023/11/2010A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHTA randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT epistaxisTrade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
INN or Proposed INN: BEVACIZUMAB
Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Other descriptive name: SODIUM CHLORIDE
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und OhrenkrankheitenNULLNot RecruitingFemale: yes
Male: yes
30Austria
13NCT01402531
(ClinicalTrials.gov)
July 22, 201019/7/2011Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: Submucosal BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll10Phase 2United States
14NCT01397695
(ClinicalTrials.gov)
June 200918/7/2011Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT)Drug: BevacizumabUniversity of California, San DiegoNULLCompleted18 YearsN/AAll20Phase 2United States
15EUCTR2008-006755-44-FR
(EUCTR)
15/01/200917/03/2009METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFOREMETAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE Maladie de Rendu-Osler
MedDRA version: 9.1;Level: LLT;Classification code 10031132;Term: Osler-Weber-Rendu disease
Trade Name: AVASTIN
Product Name: AVASTIN
INN or Proposed INN: BEVACIZUMAB
Other descriptive name: SUB16402MIG
HOSPICES CIVILS DE LYONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2France
16EUCTR2010-020545-26-IT
(EUCTR)
09/12/200810/09/2010BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - NDBEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
MedDRA version: 9.1;Level: SOC;Classification code 10005329
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
Trade Name: AVASTIN
INN or Proposed INN: Bevacizumab
AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy